STAA STAAR Surgical Company

It was the subject of a recommendation upgrade from an analyst.

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 6.4% in the pre-market session after Stifel upgraded the company from Hold to Buy and lifted its price target to $31.00 from $28.00, StreetInsider reported.

Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rallied 7% in early Tuesday trade following an upgrade from Stifel, which pointed to improving international sales momentum and favorable product mix trends. Analyst Thomas Stephan raised Stifel's rating on the ophthalmic medical device manufacturer to Buy from Hold while lifting its price target to $31 from $28.

Markets opened Tuesday on edge as surging oil prices, climbing Treasury yields, and a rejected Iran ceasefire rattled traders heading into the final stretch of Q3. Find out which major names on Wall Street got upgraded, downgraded, or freshly initiated before the opening bell.

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 6.3% in the afternoon session after the company announced that its board of directors authorized a share repurchase program of up to $50 million.

It has launched a $50 million share repurchase program.

Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect

Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rose as much as 2% in after-hours trading Thursday following the company's announcement of a $50 million share repurchase program authorized by its Board of Directors.

STAAR Surgical recently reported quarterly net sales of US$93.5 million, an increase of 111% year over year, driven largely by China where revenue more than doubled to US$52.3 million and helped swing the company to US$8.1 million in net income from a loss a year earlier. Alongside this earnings rebound, STAAR strengthened its leadership bench by appointing former CEO David Bailey as Chief Commercial Officer and Ben Park, Ph.D., as Chief Technology Officer, signaling a focus on accelerating...

Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a sharp business turnaround, with net sales rising 111% year over year and net income reaching $8.1 million, helped by China now contributing more than half of revenue. That backdrop sets the stage for two fresh executive appointments at the ophthalmic device producer. These moves could shape how the recent performance is translated into longer term commercial and product decisions. On the market...

On August 12, STAAR Surgical (NASDAQ:STAA) reported results for the quarter ended July 3 that flipped the script from a year earlier. Net sales jumped 111% year over year to $93.5 million, and the company that lost money in the same quarter of 2025 turned in $8.1 million of net income instead. It is the […]

David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

Check out the companies making headlines this week:

Record revenue and return to profitability driven by EVO Plus expansion in China.

STAAR Surgical’s second quarter results surpassed Wall Street’s expectations for both revenue and adjusted earnings, but the market reacted negatively, likely reflecting investor caution about the sustainability of recent growth. Management attributed the strong quarter to increased adoption of EVO Plus in China, ongoing market share gains from laser-based competitors, and consistent double-digit growth outside China, especially in the U.S. and EMEA. CEO Warren Foust emphasized that the company’

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) fell 8.3% in the afternoon session after sentiment faded following its underwhelming second quarter earnings reported the previous week.

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

STAAR Surgical (STAA) is back in focus after its latest earnings showed sales of US$93.54 million for the second quarter and net income of US$8.06 million, compared with a loss in the prior year. See our latest analysis for STAAR Surgical. The latest results and August leadership changes have pulled STAAR Surgical back into focus. The recent 1-day share price return of 3.36% and 7-day return of 8.14% contrast with a 90-day share price decline of 18.97% and a 5-year total shareholder return...

Medical lens company STAAR Surgical (NASDAQ:STAA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 111% year on year to $93.54 million. Its non-GAAP profit of $0.25 per share was 9.7% above analysts’ consensus estimates.

STAAR Surgical reported past second-quarter 2026 results showing sales of US$93.54 million versus US$44.32 million a year earlier, with net income of US$8.06 million replacing a net loss of US$16.81 million and earnings per share improving to US$0.16 from a US$0.34 loss. Alongside these results, the board’s recent move to appoint long-time operator Warren Foust as CEO underscores how leadership changes and an operational reset have coincided with the company’s shift back to...

STAAR Surgical (NasdaqGM: STAA) has appointed Warren Foust as permanent President and CEO and added him to the board of directors. The decision follows a period of operational reset at the company and a reported return to profitable growth under Foust's leadership. The move replaces the prior temporary co-CEO structure and signals a defined leadership direction for the ophthalmic device maker. For investors watching how leadership quality shapes execution in specialized medical technology,...

STAAR Surgical stock is coming into focus again as investors weigh a sharp share price decline over the past five years against mixed valuation signals, with one key intrinsic value estimate pointing to some upside while market based multiples suggest the shares are not cheap. STAAR Surgical shares have delivered a decline of 79.8% over the past five years, which raises questions about how much of the business risk and execution uncertainty is already reflected in the price. Expectations for...

Moby summary of STAAR Surgical Company's Q2 2026 earnings call

Staar Surgical Co (STAA) reports a 111% year-over-year net sales increase to $93.5 million, driven by robust China demand for EVO Plus, while navigating supply constraints and tariff headwinds.

STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company’s strongest first half of re

Staar Surgical (STAA) delivered earnings and revenue surprises of +47.62% and +3.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical lens company STAAR Surgical (NASDAQ:STAA) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 111% year on year to $93.54 million. Its GAAP profit of $0.16 per share was 12.6% above analysts’ consensus estimates.

Medical lens company STAAR Surgical (NASDAQ:STAA) will be reporting earnings this Wednesday after market hours. Here’s what investors should know.

Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The implantable eye lens company began searching for a new CEO shortly after its sale to Alcon collapsed in January.

Merit Medical (MMSI) delivered earnings and revenue surprises of +23.96% and +3.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical Company recently issued preliminary guidance indicating net sales for the second quarter of 2026 are expected to exceed US$90,000,000, compared with US$44,300,000 in the same quarter of 2025. This more than doubling of anticipated quarterly revenue suggests a step-change in sales momentum that could influence how investors assess the company’s operational progress. We’ll now examine how this sharp upgrade to second-quarter revenue expectations may influence STAAR Surgical’s...

A number of stocks fell in the afternoon session after a key industry player warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. The concern was raised by Intuitive Surgical, which noted that shifting insurance coverage could dampen the number of medical procedures performed in the United States. This news has investors worried about near-term demand, not just for one company, but for the entire industry reliant on a steady volu

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Staar Surgical's (STAA) recent quarterly results continue to boost confidence that the medical techn